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Lung cancer is the leading cause of cancer mortality in theUnited States and worldwide,1,2 and the prognosis remains
poor with an estimated 5-year overall survival (OS) rate of
15%.2 Approximately 85% of the cases of lung cancer are
non-small cell lung cancer (NSCLC), and the majority of
patients have advanced stage disease at the time of diagno-
sis.3 Significant investigations into the etiology, molecular
characteristics, and the development of novel therapies for
NSCLC have been performed and are ongoing. Conse-
quently, NSCLC research and care have evolved into a
multidisciplinary approach. As a variety of disciplines per-
form important research and the results are published in
multiple journals, it has become increasingly difficult to
remain current on the recent publications. We sought to
provide a concise review of the major publications related
to lung cancer in the fields of molecularly biology, surgery,
radiation oncology, and medical oncology. We restricted the
review to clinical trials that were published in peer-reviewed
journals to the calendar year of 2010; given the rapid devel-
opments within the field of molecular biology, abstracts and
presentations from 2010 and early 2011 were included in this
review. Unfortunately, no appreciable progress was made in
small cell lung cancer in the year 2010; therefore, the focus
on the review will be NSCLC.
MOLECULAR BIOLOGY
The ongoing identification of novel recurring molecular
abnormalities in lung cancer continues to present exciting
opportunities in targeted therapy for this deadly cancer. This
theme remains the defining story for lung cancer science in
the 21st century. In this brief review, there will be an effort to
discuss some of the developments in lung cancer biology and
its application to therapy.
Without doubt, the major development in 2010 that will
soon impact lung cancer therapy is the identification of
translocations of the echinoderm microtubule associated pro-
tein-like 4 (EML4) and anaplastic lymphoma kinase (ALK)
gene in NSCLC. As has been well described, the most
common abnormality activating the ALK protein is the result
of in-frame translocations between the EML4 and ALK genes.
In this acquired molecular abnormality, the ALK gene is
constitutively activated after fusion with the EML4. In 2010,
a number of presentations at the American Society of Clinical
Oncology (ASCO) Annual Meeting held in Chicago in June
demonstrated the presence of these translocations in approx-
imately 2 to 5% of NSCLC tumors. The importance of this
molecular alteration was underscored by the results of the
phase I/II study of the results of the clinical study using
crizotinib, a novel inhibitor of both ALK and c-MET. In
patients with tumors that possess a translocation, the disease
control rate for this agent has been up to 90%.4
Even now, there remains debate about the best method
for detection of ALK translocations in NSCLC. This also was
highlighted at the 2010 ASCO meeting when a number of
abstracts were presented detailing methods of fluorescent in
situ hybridization (FISH),5 polymerase chain reaction
(PCR),6–8 and immunohistochemical (IHC)9,10 systems of
detection. Although the current clinical studies have largely
relied on FISH-based methods to confirm the presence of
activating ALK translocations, all three of these technologies
seem equivalent in their sensitivity based on the data pre-
sented at the 2010 ASCO meeting. PCR has a theoretical
advantage of detecting all possible isoforms, but the advan-
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tage of this in clinical practice is unclear. The technique of
IHC would seem appealing as well, as the novel chimeric
fusion protein between EML4 and ALK should be unique, and
thus, an antibody with high specificity for this protein could
be quite useful. Other strategies in development include using
both IHC and FISH testing in an algorithm in which tumor
samples undergo initial testing with IHC; tumors that are
positive by IHC undergo confirmatory testing by FISH or
tumors that have intermediate IHC score undergo testing by
FISH to investigate for ALK rearrangement.11,12 Unfortu-
nately, although such antibodies have been reported, their
limited widespread availability remains a limiting factor in
their development and application. Of the three technologies,
both PCR and FISH have shown utility in predicting for
crizotinib sensitivity, while the application of IHC remains in
development.
Additional data presented at ASCO in 2010 confirmed
the relatively exclusive expression patterns of K-ras muta-
tions, epidermal growth factor receptor (EGFR) mutations,
and the previously mentioned EML4-ALK translocations.
Indeed, as of 2010, there is only a single case reported of a
NSCLC tumor possessing both an activating EGFR mutation
and an EML4-ALK translocation.5 In addition, the presence of
K-ras mutations, found almost exclusively in adenocarci-
noma of the lung and associated with a smoking history, has
been shown to be exclusive of these other mutations. Of
interest, Salama et al.13 demonstrated that acquired c-MET
mutations (the receptor for hepatocyte growth factor) in this
critical receptor occur in 10% or more of NSCLC tumors and
is also exclusive of the previously described mutations in
EGFR, K-ras, and translocations of ALK. A paradigm is
clearly developing that will impact clinical practice in which
up to 25 to 50% of NSCLC adenocarcinomas will soon be
characterized by the presence of mutations in one of these
genes. Targeted drugs are available or in clinical testing for
all these pathways.
There remains continued interest in a number of other
predictive markers for response to therapy in NSCLC. The
previously mentioned K-ras mutations were once described
as a significant negative predictor for benefit to adjuvant
chemotherapy in NSCLC in the JBR10 trial.14 In addition,
ERCC1 (DNA repair gene) expression has received much
interest as a potential negative marker for platinum sensitiv-
ity.15,16 Both of these markers remain under intense investi-
gation, and their utility remains unclear. The ongoing Lung
Cancer Adjuvant Cisplatin Evaluation (LACE) Bio-Consor-
tium effort grouping the major adjuvant trials in Europe and
North America continues to address these biomarkers and
their utility in guiding therapy for NSCLC.17
Serum-based markers remain an active area of interest
in lung cancer biology. In 2009, the Veristrat serum pro-
teomic test became widely available in North America. In
2010, there were data reported on the application of the
Veristrat test to blood specimens from a phase II study of
erlotinib plus bevacizumab for metastatic NSCLC.18 There
was a significant benefit retrospectively predicted for erlo-
tinib-based therapy indicated by the Veristrat test. This was
an important follow-up to previously published studies on
samples from the Eastern Cooperative Oncology Group 3503
study using first-line therapy with erlotinib in NSCLC.19
Finally, there remains continued interest in genomic
models for both prognostic and predictive use in NSCLC.
Although numerous models have been published, including
both standard messenger RNA expression profiling and mi-
RNA profiling,20,21 no model has been proven acceptable for
clinical use. The clinical lung cancer community remains
unsatisfied with the current classification of tumors based
on the arbitrary retrospective analysis of tumor size leading to
the recommendation of adjuvant therapy for tumors greater
than 4 cm. A robust and reproducible molecular assay to
identify those at high risk or relapse is sorely needed.
In summary, NSCLC will continue to be increasingly
classified by the acquired mutation profile present in the
primary tumor. Standard of care will increasingly dictate that
all NSCLC tumors be subjected to genetic testing, probably
mandating repeat biopsies in many cases. Predictive markers,
such as ERCC1, remain in development and the subject of
large scale testing by international groups. Serum markers
will continue to be the standard to which investigators should
strive, so that NSCLC may in the near future have blood tests
as valuable as the prostate-specific antigen.
STAGING
In 2007, the International Association for the Study of
Lung Cancer revised the lung cancer staging system based on
a large international database.22 Although this improved our
ability to predict outcomes of a given cohort of patients,
several authors have identified additional modifiers to predict
prognosis. Igai et al.23 demonstrated that even patients with
T1N0 lung cancer have significant differences in 5-year
disease-free survival rate if they had elevation in preoperative
carcinoembryonic antigen (50.8% versus 95.1%) and blood
or lymphatic vessel invasion (40.0% and 95.8%). This work
was corroborated by Shoji et al.24 who demonstrated that
blood vessel invasion in patients with pathologic T-1 tumors
predicted worse disease-free survival. In fact, the survival of
a pathologic T-1b lesion without blood vessel invasion was
similar to a pathologic T-1a tumor with blood vessel invasion
suggesting vascular invasion may be used to further refine
prognosis.
Accurate assessment of lymph nodes status is critical
for accurate staging. Saynak et al.25 demonstrated that metic-
ulous analysis of N1nodes (in addition to N2 nodes) and
attention to defining the N1 station improve local regional
control. Many patients had undefined (i.e., “peri-bronchial”
descriptor without defined station location) N1 nodes re-
ported as negative. These patients had higher risk of recur-
rence versus those with a negative defined N1 station (i.e.,
level 10 and level 11). Furthermore, although multiple lung
tumors in the ipsilateral lung have been downstaged from
M1a to T4 in the new staging system, the presence of nodal
disease was the largest predictor of 5-year survival rate (57%
versus 0%).26
Another key factor in staging is pleural cytology. An
international study pooling data from 22 centers demon-
strated the finding of positive cytology from saline instilled
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into a chest during surgery conferred a risk of poor outcome
similar to a single increase in the T stage.27 Aokage et al.28
refined this further by analyzing results of lavage before and
after resection in more than 2000 patients. Almost all patients
with positive postsurgical pleural lavage relapsed within 5
years. They suggest that all these patients be treated as having
advanced stage disease. The results of American College of
Surgical Oncology Group (ACOSOG) Z0040 trial, which
address this question, are expected in the coming year.
STAGING OF THE MEDIASTINUM
Newer lesser invasive strategies have become the stan-
dard for mediastinal nodal staging. Annema et al.29 demon-
strated that in patients at high risk for N2 disease (enlarged
mediastinal nodes on computed tomography, positron emis-
sion tomography-positive mediastinal or hilar nodes, and
patients with central tumors) endobronchial ultrasound
(EBUS) followed by mediastinoscopy if the EBUS was
negative was superior to mediastinoscopy alone, in avoiding
unnecessary thoracotomy. The addition of mediastinoscopy
to negative EBUS in these patients at risk for N2 disease
significantly improves the sensitivity for detection of malig-
nant N2 lymph nodes from 85 to 94% (p  0.02). Other
single-center studies confirm that in patients suspected to
have N2 disease, there is value to mediastinoscopy after a
negative EBUS. Defranchi et al.30 performed a retrospective
review of 494 patients with suspected or confirmed lung
cancer undergoing mediastinoscopy after a negative EBUS;
the nodal station-specific negative predictive value of an
EBUS was 86% (95% confidence interval [CI], 75–97%) and
the patient-specific negative predictive value of 72% (95%
CI, 56–89%). Cerfolio et al.31 found a negative predictive
value of 80% for endoscopic ultrasound (EUS) and EBUS in
patients suspected of N2 disease. Szlubowski et al.32 demon-
strated that in patients with low preoperative probability of
N2 disease, the negative predictive value of EBUS and EUS
was 91%. All patients in the study had EUS and EBUS and
surgical staging by transcervical extended mediastinal lymph-
adenectomy. The pretest probability of N2 disease should
guide the physician in determining adequacy of staging.
MINIMALLY INVASIVE SURGERY
The surgical literature continues to validate the benefi-
cial outcomes of minimally invasive video assisted thoracic
surgery (VATS) compared with thoracotomy. Traditionally,
pulmonary function tests (PFTs) have been used to predict
postoperative morbidity and mortality in patients undergoing
lung resection. In a study of 340 patients with diffusion
capacity of lung carbon monoxide or forced expiratory vol-
ume in 1 second 60% undergoing lobectomy by either
thoracotomy or VATS, there was 17% incidence of pulmo-
nary complication.33 Nevertheless, in multivariate analysis,
preoperative PFTs were significant predictors of pulmonary
morbidity only in the thoracotomy group. In patients with
poor PFTs (predicted postoperative forced expiratory volume
in 1 second  40%) who underwent anatomic lung resection,
the VATS approach conferred survival advantage illustrating
the impact of operative technique minimizing chest wall
dysfunction.34
In a large prospective study designed to assess the
efficacy of lymph node dissection versus sampling in early-
stage lung cancer, propensity analysis comparing VATS
versus open procedure revealed a significantly shorter oper-
ative time and median length of stay and a lower rate of chest
tubes draining more than 7 days with the VATS approach.35
The number of lymph nodes retrieved was equivalent, and the
operative mortality was similar. Review of the Society of
Thoracic Surgery database (a detailed nationwide data set of
US patients) identified 5042 open procedure, and 1281 pa-
tients undergoing VATS resection propensity analysis
showed not only fewer respiratory complications but also
fewer cardiovascular complications.36 Handy et al.37 reported
that VATS patients performed better or the same as open
resection in all categories of quality of life (QOL). Patients
undergoing VATS had a better preservation of preoperative
performance status; at 6 months postoperatively, use of pain
medications and hospital readmission was lower in the VATS
group.
Early criticism of VATS technique was concern about
oncologic equivalence of open thoracotomy versus VATS
resection. Flores et al. report the Memorial Sloan Kettering
experience of patients undergoing lobectomy for clinical
stage IA disease by either VATS or open resection with more
than 500 patients in each group. They report equivalent
outcomes in terms of clinical upstaging and recurrence
rates.38 Kim et al.39 further reported that in patients with
clinical stage I NSCLC resected by VATS resection but were
found to have N1 or N2 disease, they had no worse rate of
survival or recurrence when compared with open technique.
Finally, despite initial concerns that VATS is more expen-
sive, a US analysis of open versus VATS approaches docu-
mented significant cost savings to VATS approach in the first
30 days of an operation.40
EARLY-STAGE DISEASE
The introduction of stereotactic body radiotherapy
(SBRT) has radically changed management of high-risk pa-
tients with early-stage NSCLC with local tumor control rates
exceeding 90% reported across multiple studies. Neverthe-
less, the results from Radiation Therapy Oncology Group
(RTOG) 0236 are particularly meaningful as it is one of few
prospective multiinstitutional cooperative group trials that
required pathologic confirmation of NSCLC and also re-
stricted entry to high-risk patients.41 Fifty-five high-risk pa-
tients with peripheral T1 or T2 N0 NSCLC (5 cm) were
treated with SBRT to a dose of 6000 cGy in three fractions of
2000 cGy. The treated population consisted predominantly of
women (62%) and T1 lesions (80%). With follow-up of 34.4
months, only one relapse in the primary site was observed.
Local tumor control in the involved lobe was 90.6%, and
estimated 3-year survival exceeded 50%. Treatment seemed
tolerable with protocol-specified grade 3 and grade 4 toxic
events in 14% and 4% of patients, respectively. At the same
time, six additional patients had adverse events that were not
classified prospectively as protocol specified, including three
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patients with grade 3 soft tissue (skin or rib) treatment-related
complications.
Given the results of RTOG 0236, trials comparing
SBRT with surgical resection for high-risk patients seem
justified, and a phase III study comparing the RTOG SBRT
regimen with sublobar resection (brachytherapy) is
planned. In the meantime, a retrospective comparison from
William Beaumont Hospital compared SBRT and wedge
resection in 128 patients with stage I NSCLC ineligible for
anatomic lobectomy.42 After excluding patients with synchro-
nous primary lesions, SBRT was associated with reduced
local relapse (5% versus 24%), although there was no differ-
ence in cause-specific survival, freedom from any failure, or
distant metastasis between the two groups.
Although trials have not been completed directly com-
paring SBRT with traditionally fractionated radiotherapy, an
analysis of 875 elderly (75 years of age) patients diagnosed
with stage I NSCLC from the Amsterdam Cancer Registry
suggests that the introduction of SBRT had a substantial
impact on both patient care and outcomes.43 Overall radio-
therapy use increased with SBRT availability corresponding
to a decrease in untreated patients. During the most recent
time period analyzed, more than half of patients treated with
radiotherapy received SBRT. Median survival for all patients
increased from 16 months in the time period before SBRT
(1999–2001) to 21 months when SBRT was readily available
(2005–2007), and the improvement was confined to radio-
therapy patients.
An alternative strategy for treating early-stage NSCLC,
accelerated hypofractionated radiotherapy was studied by the
Cancer and Leukemia Group B (CALGB) in one of the first
prospective multiinstitutional cooperative group studies de-
signed for high-risk patients with T1N0 or T2N0 (4 cm)
NSCLC.44 Thirty-nine eligible patients meeting defined cri-
teria for pulmonary dysfunction were treated with involved
field three-dimensional conformal radiation therapy. The total
dose was kept constant at 70 Gy, whereas treatment was
reduced from 29 fractions of 2.69 Gy to 17 fractions of 4.1
Gy. Patients with either peripheral or centrally located lesions
were eligible. Overall treatment was well tolerated; there
were two grade 3 nonhematologic toxicities and no grade 4 or
greater toxicity. With median follow-up of 53 months, three
local failures have been identified (7.7%), and median sur-
vival is 38.5 months. This experience compares well with
reports of SBRT. In both RTOG 0236 and CALGB 39904,
the most common site of failure was distant, and a joint trial
is planned to assess the role of adjuvant systemic chemother-
apy after SBRT or hypofractionated radiotherapy for high-
risk patients with T1b or T2a N0 NSCLC.
ADJUVANT CHEMOTHERAPY
The NSCLC Meta-Analyses Collaborative Group per-
formed a meta-analysis using individual patient data compar-
ing surgery with chemotherapy with surgery alone based on
34 trials including 8447 patients.45 The combination of sur-
gery and chemotherapy resulted in an improvement in OS
(hazard ratio [HR]  0.86; 95% CI, 0.81–0.92; p  0.0001)
representing an absolute increase of 4% at 5 years (from 60 to
64%). A second meta-analysis compared surgery, chemo-
therapy, and radiation therapy with surgery and radiother-
apy based on 13 trials including 2660 patients.45 A benefit
of surgery, chemotherapy, and radiation compared with
surgery and radiation therapy was observed (HR  0.88,
95% CI, 0.81– 0.97; p  0.009) representing an absolute
improvement of 4% at 5 years. The effect of chemotherapy
did not differ significantly by age, sex, histology, perfor-
mance status, or stage.
Long-term results of two phase III trials of adjuvant
cisplatin-based chemotherapy, the International Adjuvant Lung
Cancer Trial and JBR-10, were reported as well (Table 1).46,47
International Adjuvant Lung Cancer Trial revealed an im-
provement in the 5-year OS rate with adjuvant chemotherapy
compared with observation, but with further follow-up (a
median follow-up of 7.5 years), this difference was not
statistically significant. The analysis for nonlung cancer
deaths for the whole study period was HR  1.34 (95% CI,
0.99–1.81; p  0.06). In JBR-10 with a median follow-up of
9.3 years, observation was associated with a higher risk of
death from lung cancer (p 0.02) with no difference in death
from other causes or second primary observed between the
treatment arms. There was a trend for interaction with disease
stage (p  0.09).
LOCALLY ADVANCED DISEASE
For patients with unresectable stage IIIA or IIIB disease
who have good performance status and adequate organ func-
tion, the combination of chemotherapy and radiation therapy
compared with radiation alone results in improved overall
survival. Multiple trials have investigated sequential chemo-
therapy and radiation compared with concurrent chemoradio-
therapy, and the NSCLC Collaborative Group performed a
meta-analysis comparing the two treatment approaches.48
Data from six trials consisting of 1205 patients were in-
cluded, and the median follow-up was 6 years. There was a
significant improvement in OS with the concurrent chemora-
diotherapy compared with sequential chemotherapy and ra-
diation (HR  0.84, 95% CI, 0.74–0.95; p  0.004) with an
absolute benefit of 5.7% at 3 years (from 18.1 to 23.8%) and
TABLE 1. Long-Term Follow-Up of Adjuvant Cisplatin-
Based Chemotherapy Trials
First Author





Intent to treat 0.91 (95% CI, 0.81–1.02; p  0.10) 0.006
5 yra 0.86 (95% CI, 0.76–0.97; p  0.01)
5 yra 1.45 (95% CI, 1.02–2.07; p  0.04)
Butts et al.47
Intent to treat 0.78 (95% CI, 0.61–0.99; p  0.04) 0.09
Stage IB 1.03 (95% CI, 0.7–1.52; p  0.82)
Stage II 0.68 (95% CI, 0.5–0.92; p  0.01)
a The data in related to 5 yr and 5 yr are data from the update publication by
Arriagada et al.46
CI, confidence interval.
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4.5% (from 10.6 to 15.1%) at 5 years. Concurrent therapy
reduced the rate of loco-regional progression (HR  0.77,
95% CI, 0.62–0.95; p  0.01) but had no impact on distant
disease progression (HR  1.04, 95% CI, 0.86–1.25; p 
0.69). The rate of grade 3 or 4 esophageal toxicity was
increased with concurrent therapy from 4 to 18% (relative
risk of 4.9, 95% CI, 3.1–7.8; p  0.001). This analysis
provides an accurate estimate of the long-term benefit and
increased esophageal toxicity associated with concurrent che-
moradiotherapy.
Most of the trials that have investigated concurrent
chemoradiotherapy compared with sequential chemotherapy
and radiation have been employed older or second-generation
chemotherapy combinations.49,50 In 2010, two phase III trials
which compared second-generation with third-generation
combinations concurrent with thoracic radiation were pub-
lished. The West of Japan Thoracic Oncology Group com-
pared four cycles of mitomycin, vindesine, and cisplatin
(MVP) with thoracic radiation therapy (TRT) (arm A) with
the concurrent carboplatin (area under the curve [AUC] of 2)
and irinotecan 20 mg/m2 weekly for 6 weeks with TRT to 60
Gy followed by two cycles of carboplatin (AUC of 5) and
irinotecan 50 mg/m2 days 1, 8 every 21 days (arm B) or
carboplatin (AUC of 2) and paclitaxel (40 mg/m2) weekly for
6 weeks concurrent with TRT followed by two cycles of
carboplatin (AUC of 5) and paclitaxel (200 mg/m2) every 21
days (arm C).51 The median OS and 5-year OS observed in all
three arms were similar (Table 2). The rate of grade 3 or 4
neutropenia, febrile neutropenia, and gastrointestinal toxicity
was significantly higher in arm A than arm B or C. The
Okayama Lung Cancer Study Group performed a phase III
trial, which compared MVP with cisplatin (40 mg/m2) and
docetaxel (30 mg/m2) on days 1, 8, 29, and 36 with TRT.52
The OS at 2 years and the primary endpoint favored the
cisplatin and docetaxel arm compared with the MVP arm
(p  0.056), and the median OS was similar (Table 2). The
rate of grade 3 febrile neutropenia was higher in the MVP
compared with the cisplatin and docetaxel (39% versus 22%,
p 0.012), and the rate of grade 3 or 4 esophagitis was lower
(6% versus 14%, p  0.056). These two trials suggest that
carboplatin/paclitaxel and cisplatin/docetaxel are acceptable
chemotherapy combinations with TRT of 60 Gy.
The potential promise and perils of combining molec-
ular targeted agents with (chemo) radiotherapy were illus-
trated in recent reports of prospective trials for locally ad-
vanced disease. CALGB 30106 evaluated the addition of the
EGFR gefitinib to sequential or concurrent chemoradiother-
apy in unresectable stage III NSCLC.53 After two cycles of
induction paclitaxel and carboplatin chemotherapy, a poor-
risk stratum (5% weight loss and/or PS 2) received radio-
therapy to 66 Gy and gefitinib 250 mg daily, whereas a
normal-risk stratum received the same radiotherapy/gefitinib
regimen plus weekly paclitaxel and carboplatin. Treatment
was well tolerated without unexpected toxicity. Surpris-
ingly, the median survival of the poor-risk cohort reached
19 months, whereas the median survival of the normal-risk
cohort was only 13 months, suggesting potential synergy
between the EGFR inhibitor and radiotherapy that may be
abrogated by concurrent chemotherapy. The trial was pre-
maturely terminated based on data from external trials
using gefitinib, but a follow-up study assessing erlotinib
and radiotherapy in poor-risk patients (CALGB 30605) is
near completion.
On the other hand, integration of the antiangiogenic
agent bevacizumab with combined modality therapy has been
more challenging. A report from the Sarah Cannon Oncology
Research Consortium included data on prospective phase II
trials in limited stage small cell lung cancer and NSCLC
combining bevacizumab with radiation and chemotherapy.54
Both trials were closed early due to severe toxicity. Of 29
patients in the limited stage small cell lung cancer study, two
patients developed tracheoesophgeal fistulae and one addi-
tional patient died of aerodigestive hemorrhage. Moreover,
two of only five patients accrued to the NSCLC trial devel-
oped tracheoesophgeal fistulae.
TRIMODALITY THERAPY
The landmark 2009 trial of trimodality compared with
chemoradiotherapy for patients with stage IIIA lung cancer
revealed no difference in OS in the intent-to-treat patient
population.55 The postoperative mortality among patients
undergoing pneumonectomy after chemoradiotherapy was
prohibitive. A subset analysis of patients who received che-
moradiotherapy followed by lobectomy compared with
TABLE 2. Phase III Trials Comparing Chemotherapy Combinations with Concurrent Thoracic
Radiation
Authors Chemotherapy (Number) TRT Median OS 5-yr OS
Yamamoto et al.51 Mitomycin, vindesine, cisplatin (N  146) 60 Gy 20.5 mo 17.5%
Carboplatin, irinotecana (N  147) 60 Gy 19.8 mo 17.8%
Carboplatin, paclitaxelb (N  147) 60 Gy 22.0 mo 19.8%
Segawa et al.52 Mitomycin, vindesine, cisplatin (N  99) 60 Gy 23.7 mo NR
Cisplatin, docetaxelc (N  99) 60 Gy 26.8 mo NR
a Treatment was carboplatin AUC  2 and irinotecan 20 mg/m2 weekly for 6 wk concurrent with TRT, followed by carboplatin AUC 
5 and irinotecan 50 mg/m2 day 1 and day 8 every 21 d for two cycles.
b Treatment was carboplatin AUC  2 and paclitaxel 40 mg/m2 weekly for 6 wk concurrent with TRT followed by carboplatin AUC 
5 and paclitaxel 200 mg/m2 every 21 d for two cycles.
c Treatment was cisplatin 40 mg/m2 and docetaxel 40 mg/m2 on days 1, 8, 29, and 36.
OS, overall survival; NR, not reported; TRT, thoracic radiation therapy.
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matched patients who received chemoradiotherapy alone sug-
gested that neoadjuvant chemoradiotherapy followed by re-
section conferred a survival advantage. Survival was highest
for those who were downstaged to pathologic N0 or N1
disease compared with persistent N2 disease (45% versus
20%). European centers report a lack of surgical morbidity
for patients undergoing a pneumonectomy after neoadjuvant
therapy.56 In 827 patients in whom 80% of who received
chemotherapy and radiation and 176 pneumonectomies were
performed, the 90-day mortality was 3%, and 5-year survival
was 38%. Using neoadjuvant chemotherapy alone, Stefani et
al.57 report a mortality of 4.5% after surgical resection; 79 of
the 175 patients underwent pneumonectomy. Similar to other
reports, clinical downstaging was predictive of survival. Five-
year OS was higher with among patients who responded to
chemotherapy (5-year OS rate of 42% was observed among
patients who experienced a response and 10% among nonre-
sponders) and mediastinal downstaging (5-year OS rate of
45% was observed among patients with mediastinal nodal
clearance and 22% for patients with persistent N2 nodal
involvement). These studies indicate the importance of reas-
sessing patients after neoadjuvant therapy to ensure that they
are still candidates for surgical resection.
In support of the safety of neoadjuvant therapy, a
review of the American Society Thoracic Surgery database
and propensity analysis revealed no difference in mortality
between patients undergoing neoadjuvant chemotherapy fol-
lowed by surgery and surgery alone.58 The University of
Maryland group extended the regimen of trimodality therapy
to given mean radiation dose of 61.1 Gy. In the 29 patients
treated by pneumonectomy, the 90-day mortality was 3.4%;
15 of these patients underwent right pneumonectomy.59
ADVANCED STAGE DISEASE
Although there is lot of excitement and enthusiasm in
the oncology community regarding molecularly targeted ther-
apies, majority of clinical trials in patients with advanced
cancer are designed somewhat empirically and are seldom
driven by biomarker-based patient selection. In a review of
the ongoing clinical trials in NSCLC listed on the clinical-
Trials.gov data base, Subramanian et al.60 reported that only
7.9% of clinical trials in NSCLC were biomarker driven.
The results of subset analysis from the Iressa Pan-Asia
study published in 2009 revealed that patients with an EGFR
mutation experience a statistically significant superior re-
sponse rate and progression-free survival (PFS) with gefitinib
compared with carboplatin and paclitaxel in the first-line
setting.61 A separate trial screened lung cancers from 2105
patients for EGFR mutations, and EGFR mutations were
detected in 350 tumors; 217 patients with an EGFR mutation-
positive tumors received erlotinib.62 The median PFS and OS
were 14 months and 27 months, respectively. Two phase III
trials published in 2010 were selected for the presence of an
EGFR mutation for enrollment and compared platinum-based
double-agent chemotherapy with gefitinib. In both trials,
patients in the gefitinib treatment arm experienced a statisti-
cally significant superior response rate and PFS (Table 3).63,64
These results confirm that for patients with an EGFR muta-
tion, first-line therapy with EGFR tyrosine kinase inhibitor is
a standard of care.
The identification of oncogenic fusion gene consisting
of the EML4-ALK in subgroup of patients with NSCLC has
allowed for the development of crizotinib, a small molecule
inhibitor of the ALK tyrosine kinase.4 This agent was inves-
tigated in phase I/II trial with an expanded cohort in patients
with advanced NSCLC demonstrating the presence of the
ALK rearrangement; of the 1500 patients with NSCLC, ALK
rearrangements were identified in 82 patients. The mean
treatment duration was 6.4 months, and the overall response
rate observed was 57%, and the rate of stable disease was
33%. The 6-month PFS observed was 72%, and the median
PFS has not been reached. The most common adverse events
were grade 1 or 2 gastrointestinal events, and 41% of patients
reported mild visual disturbances. Grade 3 elevations of the
alanine aminotransferase and aspartate aminotransferase were
observed in 5% and 6% of patients.
An intriguing trial investigated the early integration of
palliative care with standard therapy to standard therapy for
patients with advanced NSCLC; the primary endpoint was
QOL at 12 weeks.65 Patients assigned to early palliative care
compared with the patients assigned to standard therapy had
a statistically significant better QOL, a lower rate of depres-
sive symptoms, and a longer median survival (11.6 versus 8.9
months, p  0.02). Patients in the early palliative care arm
received aggressive end-of-life care (defined as any of the
following three criteria: chemotherapy within 14 days of
death, no hospice care, or admission to hospice  3 days
before death) at a lower rate (33% versus 54%, p  0.05).
TABLE 3. First-Line Trials Comparing EGFR-TKI with Platinum-Based Chemotherapy
Authors Treatment Arm ORR Median PFS Median OS
Maemondo et al.64 Gefitinib (N  115) 73.7% 10.8 mo 30.5 mo
Carboplatin  paclitaxel (N  115) 30.7% 5.4 mo 23.6 mo
p  0.001 HR  0.30, p  0.001 p  0.31
Mitsudomi et al.63 Gefitinib (N  86) 62.1% 9.2 mo Not availablea
Cisplatin  docetaxel (N  86) 32.2% 6.3 mo Not available
p  0.0001 HR  0.489, p  0.0001
a Survival data immature due to the low number of events in both arms.
ORR, overall response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; EGFR-TKI, epidermal growth factor
receptor-tyrosine kinase inhibitor.
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CONCLUSIONS
In summary, it is very clear that therapeutic impact is
greater when critical oncogenic drivers are targeted for ther-
apy. The challenge in the coming years is to identify and
validate significant and recurring molecular changes in large
numbers of carefully selected specimens from patients with
lung cancer. Ongoing studies using massively parallel-se-
quencing technologies will hopefully reveal a significant
number of new targets. Not only this effort will spur interest
in developing novel agents but also should force us to
consider reevaluating some agents deemed ineffective when
used previously in a group of unselected patients.
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